complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Genre:||Health and Food|
|Published (Last):||2 April 2016|
|PDF File Size:||16.75 Mb|
|ePub File Size:||18.25 Mb|
|Price:||Free* [*Free Regsitration Required]|
Previous irradiation to the left chest is associated with an increased risk of developing CHF and an accelerated mortality.
Epirubicin is a FDA pregnancy category D agent. Epirubicin is considered cell cycle non-specific.
Two cases of acute lymphoid leukemia ALL have been reported in patients receiving epirubicin. The red urine should not be confused with hematuria.
mecanismo de acción de antineoplasicos by angel vasquez garcia on Prezi
Due to the thrombocytopenic effects of epirubicin, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents. Epirubicin has also been studied in combination with vinorelbine and as a single-agent therapy.
Epirubicin has a similar spectrum of activity and toxicity as doxorubicin. Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non-small cell lung cancer. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
If possible, avoid veins over joints or in extremities with compromised venous or lymphatic drainage. If a woman becomes pregnant during therapy, she should mecanismp advised of the potential risks to the fetus.
Medicamentos de quimioterapia
A doxorruubicina woman with breast cancer metastatic to the liver received fluorouracil, cyclophosphamide and epirubicin but was removed from the trial due to the pregnancy. A radiation recall reaction can occur after epirubicin administration at the sites of prior radiation. Extravasation of epirubicin infusions should be avoided. Following skin or ocular exposure, skin and eyes should be thoroughly rinsed. These reactions are associated with excessively rapid mexanismo and do not contraindicate further use.
Some antineoplastic agents have been reported to decrease the absorption of digoxin tablets due to their adverse effects on the GI mucosa; no significant change was seen with digoxin capsules, doxorrubjcina the effect on digoxin liquid is not known.
Surgical follow-up is indicated if pain and swelling at the site continues 2 weeks after the extravasation.
Epirubicinol has the one-tenth the cytotoxic activity of epirubicin and is not likely to contribute to the overall cytotoxic activity of epirubicin.
Patients, especially those with dental disease, should be instructed in proper oral hygiene, including caution in use of regular toothbrushes, dental floss, and toothpicks. Epirubicin has similar response rates to doxorubicin in non-small cell and small cell lung cancer, non-Hodgkin’s lymphoma, ovarian cancer, gastric cancer and hepatocellular carcinoma. Four years experience of primary mecaniemo chemotherapy PIAC for locally advanced and recurrent breast cancer.
Patients with a history of varicella zoster, other herpes infections e. The esophagus can be especially sensitive. Epirubicin also affects topoisomerase II, an enzyme responsible for DNA strand mecahismo during transcription.
Tumor lysis syndrome may occur due to treatment with epirubicin; appropriate measures e. Due to the risk of long-term cardiotoxicity, it has been recommended that children treated with anthracyclines should undergo screening with ECGs and echocardiograms every 2 years and hour continuous ECGs and df angiograms every 5 years. Unfortunately, trifluoperazine and verapamil must be given in toxic doses to achieve this positive effect.
It is prudent to closely monitor patients for loss of mecahismo efficacy of digoxin while receiving antineoplastic therapy. Age does affect the clearance of epirubicin in female patients. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Conjunctivitis and keratitis have been reported with epirubicin chemotherapy. The ECF regimen resulted in an increased response and survival benefit for patients with previously untreated gastric cancer or head and neck cancer.
Intramuscular administration and subcutaneous administration of epirubicin are contraindicated due to severe skin and tissue necrosis. The correct dose of epirubicin will vary from protocol to protocol. A accioj flare reaction has been noted in patients who receive epirubicin. Additionally, the free radicals crosslink sulfhydryl groups of calcium-release channels and inhibit Ca-ATPase which leads to extensive depletion of sarcoplasmic reticulum SR calcium stores and prevents restoration of calcium stores in the SR, respectively.
When exposed to a vaccine-preventable disease such as measles, severely immunocompromised children should be considered susceptible regardless of their vaccination history. The suggested maximum tolerated dose MTD for epirubicin, which is dependent on performance status, other chemotherapy agents or radiation given in combination, and disease state, is as follows: Other mechanisms of resistance include changes in topoisomerase II and glutathione activity.
Vaccination during chemotherapy or radiation therapy should be avoided because the antibody response is suboptimal. Alopecia occurs in almost all patients receiving epirubicin therapy. Due to rapid lysis of emcanismo cells by epirubicin, serum uric acid levels may increase. She experienced a spontaneous abortion. Epirubicin-derived free radicals can induce acvion lipid peroxidation, DNA strand scission, and direct oxidation of purine or pyrimidine bases, thiols and amines. Epirubicin and its major metabolites are excreted through biliary excretion and to a lesser extent urinary excretion.
Concurrent use of epirubicin with other agents that cause bone marrow or immune suppression such as other antineoplastic agents or immunosuppressives may result in additive effects.
The decreased incidence of clinically significant cardiac toxicity associated with epirubicin as compared to doxorubicin is due to the more rapid clearance of epirubicin and possibly, glucuronidation of epirubicin.